2026年11月4日星期三
M
Rekod Semesta
Berita Pantas Global
US experts warm to Japanese nuclear subs as check on China in Asian waters— 日经 Nikkei AsiaDRAM prices double in 2026 as AI focus squeezes PC makers— 日经 Nikkei AsiaJapan weighs standards for self-driving cars without steering wheels— 日经 Nikkei AsiaMitsubishi to sell part of stake in Canada LNG project to Blackstone funds— 日经 Nikkei AsiaJapan's SBI to invest in US digital bank Erebor, eyeing blockchain settlements— 日经 Nikkei AsiaAnthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaUS midterms live: Flooding forces polling sites to relocate— 日经 Nikkei AsiaUS experts warm to Japanese nuclear subs as check on China in Asian waters— 日经 Nikkei AsiaDRAM prices double in 2026 as AI focus squeezes PC makers— 日经 Nikkei AsiaJapan weighs standards for self-driving cars without steering wheels— 日经 Nikkei AsiaMitsubishi to sell part of stake in Canada LNG project to Blackstone funds— 日经 Nikkei AsiaJapan's SBI to invest in US digital bank Erebor, eyeing blockchain settlements— 日经 Nikkei AsiaAnthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaUS midterms live: Flooding forces polling sites to relocate— 日经 Nikkei Asia

Pembrolizumab plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer with PD-L1 CPS ≥ 1: a cost-effectiveness analysis

Sumber Nature 医学研究3 hari lalu
Ringkasan kandungan

Laman ini hanya menyediakan indeks tajuk dan ringkasan, kandungan penuh dan hak cipta adalah milik pihak penerbit asal, sila klik pautan asal untuk membaca.

Pergi ke artikel asal
Saluran berkaitan
Kesihatan
Kawasan berkaitan
Perspektif global
Bahasa teks asal
English
Nombor entri
health-c6740a8b

Comments 0 comments

No comments yet. Be the first.

Pembrolizumab plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer with PD-L1 CPS ≥ 1: a cost-effectiveness analysis · Rekod Semesta